KRAS and cancer: These findings collectively suggest that the Poloppins selectively engage the PBD1–4 target domains, and, furthermore, that suppression of PLK1 and PLK4 underlies their key cellular effects in triggering mitotic arrest, and in killing cancer cells that express mutant oncogenic KRAS.